Hui Zhang

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wanhong Zhao, Jie Liu, Baiyan Wang et al. · Journal of Hematology & Oncology · 2018 · 526 citations · Full text

Immunology, Immunodominance, Immunotherapeutics +19

Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection

Hui Zhang, Hong‐Bao Li, Jianrui Lyu et al. · International Journal of Infectious Diseases · 2020 · 311 citations · Full text

Clinical Symptoms, Microbial Pathogens, Viral Diagnostics +23

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Wanhong Zhao, Baiyan Wang, Lijuan Chen et al. · Journal of Hematology & Oncology · 2022 · 139 citations · Full text

Involvement of Oxidative Stress in the Relapse of Acute Myeloid Leukemia

Fuling Zhou, Wanggang Zhang, Yongchang Wei et al. · Journal of Biological Chemistry · 2010 · 120 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Acute Myeloid Leukemia +11

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Baiyan Wang, Wanhong Zhao, Jie Liu et al. · Blood · 2019 · 91 citations